Apatinib, commonly known as Apatinib Mesylate Tablets, acts on vascular endothelial growth factor receptor to inhibit tumor angiogenesis and thus inhibit tumor growth, and can be used to treat patients with advanced gastro-esophageal junction adenocarcinoma or gastric adenocarcinoma or patients who have relapsed or are still progressing after having received at least 2 previous systemic chemotherapies. Side effects such as gastrointestinal bleeding, hypertension, malaise, and prolonged QT interval may be experienced. The drug has cardiotoxicity and liver and kidney toxicity, so during the treatment, prolongation of QT interval and other drugs that have effects on liver and kidney functions should be used with caution, and ECG and liver and kidney functions should be closely monitored during the treatment. In addition, it has reproductive toxicity, so male and female patients of childbearing age should be contracepted during treatment and within 8 weeks of stopping treatment. It is contraindicated in the following conditions: hypersensitivity to the drug; NYHA class III-IV cardiac insufficiency; severe hepatic or renal insufficiency; within 30 days of major surgery; active bleeding, intestinal perforation, intestinal obstruction, etc.; poorly controlled hypertension. it is not recommended for patients under 18 years of age. If you need to use the drug, please be sure to strictly follow the doctor’s instructions under the guidance of the medication, do not self-medication.